Cat Number: 92210ES

LR3 IGF-1

Inquiry

Genus

Human

Source

E.coli

Synonyms

LR3 IGF-I, IBP1, IGF1, IGF-1, IGF1A, IGFI, IGF-I, IGF-IA, IGF-IB, MGF

Description

Long R3 IGF-I (LR3 IGF-I) is a 9.2 kDa synthetic analog of IGF-I that is generated by modifying the aa sequence for mature human IGF-I. The LR3IGF-1 is a long-term analog of human IGF-1, specifically designed and manufactured for mammalian cell culture to support large-scale manufacturing of recombinant biopharmaceuticals. LR3 IGF-I, an analogue of insulin-like growth factor (IGF)-I, was used in biopharmaceutical protein production in mammalian cells.

Molecular Weight

Approximately 9.1 kDa.

AA sequence

MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA

Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Purity

>96% by SDS-PAGE analyses.

Biological Activity

1.Fully biologically active when compared to standard. Measured in a serum-free cell proliferation assay using human MCF-7 cells. The ED50 for this effect is 0.3-1.5 ng/mL, corresponding to a specific activity of > 6.7 × 105 U/mg. 2.The ED50 as determined by the stimulation of protein synthesis using rat L6 myoblasts is less than 10 ng/mL, corresponding to a specific activity of > 1.0 × 105 U/mg. Fully biologically active when compared to standard.

Endotoxin

< 0.01 EU per 1μg of the protein by the LAL method.

Formulation

Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.2.

Reconstitution

1.This vial must be briefly centrifuged prior to opening to bring the contents to the bottom. 2.Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.

Note

5, 100μg, 1mg